Indications for the neoadjuvant or definitive chemoradiotherapy in esophagus carcinoma secured in the highest level of evidence;Indikationen zur neoadjuvanten oder definitiven Radiochemotherapie beim Ösophaguskarzinom auf höchstem Evidenzniveau gesichert

Strahlentherapie und Onkologie

Volumn 188, Issue 10, 2012, Pages 949-950

  Guckenberger, M ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; NOTE; TREATMENT INDICATION;

EID: 84866742345     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-012-0213-1     Document Type: Note

References (6)

1. Kranzfelder M, Schuster T, Geinitz H et al (2011) Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg 98:768-783
2. Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681-692
3. Gebski V, Burmeister B, Smithers BM et al (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8:226-234
4. Stahl M, Walz MK, Stuschke M et al (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851-856
5. Brundage MD, Davidson JR, Mackillop WJ (1997) Trading treatment toxicity for survival in locally advanced non-small cell lung cancer. J Clin Oncol 15:330-340
6. McNeil BJ, Weichselbaum R, Pauker SG (1978) Fallacy of the five-year survival in lung cancer. N Engl J Med 299:1397-1401